Full-stack LIMS
Role-based dashboards and API hooks kept wet-lab teams, bioinformaticians, and leadership in sync without forcing custom software builds.
Exit spotlight
GenoLogics | LIMS Story & Exit to Illumina | Listwin Ventures
The GenoLogics story: a laboratory information management platform for genomics labs, plus Don Listwin’s investment perspective and Illumina exit context.
Clinic-ready compliance
Configurable SOP templating, audit trails, and validation tooling let CLIA/CAP labs move from pilot studies to regulated diagnostics faster.
Acquirer integration
Bringing GenoLogics into Illumina ensured new chemistries and automation hardware shipped with cloud workflows that were proven in the field.
References
Related reading
Interview
Teradici (HP Anyware) • Aug 10, 2016
Inside Teradici: Getting to Know Don Listwin, Chairman
Q&A with Don Listwin on leadership, cloud computing, and his investment perspective in networking and software.
Momentum
A timeline from lab benches to Illumina
GenoLogics scaled with the exact needs of translational researchers, ending with an acquisition that made Illumina’s workflows even more turnkey for hospital-grade programs.
2003–2005
Origins in proteomics labs
GenoLogics built configurable lab information management software (LIMS) so translational researchers could tie together instruments, SOPs, and growing volumes of proteomics data.
2006–2010
NGS acceleration
Next-generation sequencing took off and the platform evolved to coordinate sample prep, run planning, and QC reporting so research hospitals could scale their programs.
2012–2015
Acquisition by Illumina
Illumina acquired GenoLogics in 2015 to deliver tighter workflows between the sequencer hardware, BaseSpace, and the labs driving precision-medicine advances.
Why it matters now
Precision-medicine labs still need builders
GenoLogics validated Don’s thesis: pairing disciplined software operators with bioengineering unlocks durable value. If you are building the next LIMS, diagnostics workflow, or data router for clinical genomics, reach out.